Docoh
Loading...

TGTX TG Therapeutics

TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY.

Company profile

Ticker
TGTX
Exchange
CEO
Michael Weiss
Employees
Incorporated
Location
Fiscal year end
Former names
ATLANTIC PHARMACEUTICALS INC, ATLANTIC TECHNOLOGY VENTURES INC, MANHATTAN PHARMACEUTICALS INC
SEC CIK
IRS number
363898269

TGTX stock data

(
)

Press releases

Pro users get this 30m faster
TG Therapeutics Completes Rolling Submission of Biologics License Application to the U.S. Food and Drug Administration for Ublituximab in Combination with UKONIQ™(umbralisib) as a Treatment for Patients with Chronic Lymphocytic Leukemia
29 Mar 21
NEW YORK, March 29, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced the completion of the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug
TG Therapeutics Announces Publication of Results from the UNITY-NHL Phase 2b Trial Evaluating Umbralisib Monotherapy in Patients with Relapsed or Refractory Indolent non-Hodgkin Lymphoma in the Journal of Clinical Oncology
9 Mar 21
NEW YORK, March 09, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX) today announced the publication of results from the UNITY-NHL Phase 2b trial evaluating UKONIQ™ (umbralisib), the Company's
TG Therapeutics to Present Results from the ULTIMATE I & II Phase 3 Trials Evaluating Ublituximab in Multiple Sclerosis at the Upcoming American Academy of Neurology 73rd Annual Meeting
4 Mar 21
NEW YORK, March 04, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced that results of the ULTIMATE I & II Phase 3 trials evaluating ublituximab, the Company's novel, glycoengineered
TG Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference
4 Mar 21
TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2020 Financial Results
2 Mar 21

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

1 Mar 21
11 Apr 21
31 Dec 21
Quarter (USD)
Dec 20 Sep 20 Jun 20 Mar 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 554.7M 554.7M 554.7M 554.7M 554.7M 554.7M
Cash burn (monthly) (positive/no burn) (positive/no burn) 28.93M 22.8M 17.34M 17.88M
Cash used (since last report) n/a n/a 97.63M 76.95M 58.53M 60.33M
Cash remaining n/a n/a 457.07M 477.75M 496.17M 494.37M
Runway (months of cash) n/a n/a 15.8 21.0 28.6 27.7

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
30 Dec 20 Power Sean A COMMON STOCK Grant Aquire A No No 0 20,000 0 653,338
28 Dec 20 Weiss Michael S COMMON STOCK Gift Dispose G Yes No 0 655 0 13,068,082
28 Dec 20 Weiss Michael S COMMON STOCK Gift Dispose G No No 0 1,000 0 13,068,737
22 Dec 20 Weiss Michael S COMMON STOCK Gift Dispose G No No 0 200 0 13,069,737
21 Dec 20 Power Sean A COMMON STOCK Gift Dispose G No No 0 7,000 0 629,438
15 Dec 20 Weiss Michael S COMMON STOCK Gift Dispose G No No 0 200 0 13,069,937
15 Dec 20 Weiss Michael S COMMON STOCK Gift Dispose G No No 0 1,700 0 13,070,137
15 Dec 20 Weiss Michael S COMMON STOCK Gift Dispose G No No 0 834,877 0 13,071,837
10 Dec 20 Echelard Yann COMMON STOCK Sell Dispose S No No 40.05 30,000 1.2M 129,116
9 Oct 20 Power Sean A COMMON STOCK Gift Dispose G No No 0 125,000 0 636,438

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

71.1% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 250 179 +39.7%
Opened positions 87 31 +180.6%
Closed positions 16 25 -36.0%
Increased positions 76 72 +5.6%
Reduced positions 57 50 +14.0%
13F shares
Current Prev Q Change
Total value 5.8B 3.28B +76.6%
Total shares 99.9M 86.39M +15.6%
Total puts 1.02M 929.3K +9.5%
Total calls 1.55M 1.17M +32.7%
Total put/call ratio 0.7 0.8 -17.5%
Largest owners
Shares Value Change
FMR 14.83M $771.31M +35.3%
Vanguard 10.97M $570.7M +46.5%
Ra Capital Management 8.69M $451.82M -1.6%
BLK Blackrock 8.56M $445.1M +11.3%
Wellington Management 4.92M $255.83M +48.7%
Lord, Abbett & Co. 4.44M $230.99M -11.2%
Alkeon Capital Management 4.08M $212.15M +47.0%
STT State Street 3.71M $193.14M -9.6%
Maverick Capital 3.2M $166.57M -27.1%
IVZ Invesco 1.78M $92.66M +68.0%
Largest transactions
Shares Bought/sold Change
FMR 14.83M +3.87M +35.3%
Vanguard 10.97M +3.48M +46.5%
Wellington Management 4.92M +1.61M +48.7%
Great Point Partners 0 -1.6M EXIT
TROW T. Rowe Price 1.4M +1.35M +2646.3%
Alkeon Capital Management 4.08M +1.3M +47.0%
Norges Bank 1.28M +1.28M NEW
Maverick Capital 3.2M -1.19M -27.1%
Logos Global Management 850K -900K -51.4%
BLK Blackrock 8.56M +871.57K +11.3%

Financial report summary

?
Management Discussion
  • License Revenue. License revenue was approximately $152,000 for each of the years ended December 31, 2020 and 2019. License revenue is related to the amortization of an upfront payment of $2.0 million associated with our license agreement with Ildong. The upfront payment from Ildong will be recognized as license revenue on a straight-line basis through December 2025, which represents the estimated period over which we will have certain ongoing responsibilities under the sublicense agreement.
  • Noncash Stock Expense Associated with In-Licensing Agreement (Research and Development). Noncash stock expense associated with in-licensing agreement (research and development) amounted to zero for the year ended December 31, 2020, as compared to $0.1 million during the comparable period in 2019.
  • Noncash Compensation Expense (Research and Development). Noncash compensation expense (research and development) related to equity incentive grants totaled $14.0 million for the year ended December 31, 2020, as compared to $5.8 million during the comparable period in 2019. The increase in noncash compensation expense was primarily due to an increase in research and development personnel and a higher stock price during the year ended December 31, 2020.
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg
New words: abnormal, abnormally, abundance, advocacy, age, AKS, ALT, altogether, argument, AST, atrial, backlog, barrier, behaving, bidding, Biden, biology, bleeding, bona, budgetary, built, causality, caution, CCPA, chose, cleanup, color, CPRA, cultivate, cybersecurity, debilitating, deferral, depression, destruction, detention, disallowed, discriminate, discrimination, disgorgement, distancing, domestic, driven, DSCSA, Dysregulation, ECs, EEA, elevated, epidemic, Epizyme, exacerbated, explicitly, fallout, fastest, feel, fibrillation, fide, Florida, footprint, foster, FTC, FTCA, fulfill, fulfilling, garner, GDPR, gender, globe, hear, heightened, heightening, home, hypertension, IA, immunological, immunosuppressive, inclusion, inclusive, inconsistent, indeterminate, infection, Justice, Lanham, leakage, learning, legislature, legitimize, leukopenia, marital, Mexico, mount, navigate, Nevada, NOL, notification, nurse, ODD, oncoprotein, opportunistic, opt, organizational, orientation, outbreak, pandemic, paramount, payroll, pendency, persist, pharmacovigilance, phosphoinositide, PHS, pioneering, postmarketing, pre, preapproval, pride, prioritization, QD, quarantine, rash, recession, redisclosure, registry, reinterpreted, religion, reluctance, remote, remotely, rescission, resume, Riley, Russia, salary, sexual, Shield, shipping, skilled, slowdown, slowest, sophisticated, sought, spread, spreading, Squibb, strictly, strive, stronger, subsidized, sugar, tazemetostat, thrombocytopenia, tracing, transport, travel, UKONIQ, UKONIQTM, umbrella, uMRD, underinsured, unimpeded, UNITY, unlawful, untrue, vaccination, variant, verification, veteran, virtually, Waldenstrom, weigh, wholesale, workplace, Wuhan
Removed: AACR, aberrant, Advisor, apportioned, ASCO, assume, begun, Belgium, Biogen, blocked, Cannon, capitalization, carfilzomib, certify, Chicago, Columbia, condensed, confusion, content, coupled, cytotoxic, DCD, death, deliver, demonstration, deplete, depleting, Dr, enabling, estimation, exceeding, exert, falling, Fc, forfeit, Genentech, House, Howard, Idec, identity, IL, inappropriately, inspect, intending, likewise, liver, marketable, match, Modernization, myeloma, nanomolar, Nashville, NCE, negotiating, NK, nondeductible, notably, object, ordered, ordinarily, origin, oversee, Owen, packaged, PCD, poverty, predominantly, Presbyterian, presidential, proteasome, proving, ratably, recognition, referenced, reflected, removing, reproduced, Sarah, session, show, silence, Simultaneously, Skip, strongly, substitute, supplemental, surface, synergy, TN, today, unproven, vested, waive